Home » FDA Designates Zealand Product as Orphan Drug
FDA Designates Zealand Product as Orphan Drug
October 31, 2017
The FDA granted an orphan-drug designation to Zealand’s glepaglutide medication for short-bowel syndrome.
Zealand, based in Denmark, said the drug completed phase II clinical trials, with phase III trials planned for 2018.
Short-bowel syndrome can occur after major intestinal surgery for Crohn’s disease, ischemia, radiation damage and other conditions. It can result in complete loss of intestinal function.
Upcoming Events
-
21Oct